Omega

Hauptinformation

  • Handelsname:
  • Omega 3 Cor - 1 A Pharma
  • Darreichungsform:
  • Weichkapsel
  • Zusammensetzung:
  • Omega-3-Säurenethylester 90 1000.mg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Omega 3 Cor - 1 A Pharma
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • 84501.00.00
  • Letzte Änderung:
  • 11-04-2018

24-3-2018

EMA bewertet die Anwendung von Omega-3-Fettsäure-haltigen Arzneimitteln nach Herzinfarkt

EMA bewertet die Anwendung von Omega-3-Fettsäure-haltigen Arzneimitteln nach Herzinfarkt

Das BfArM informiert über die Einleitung eines europäischen Risikobewertungsverfahrens nach Artikel 31 der Richtlinie 2001/83/EG zur Anwendung von Omega-3-Fettsäure-haltigen Arzneimitteln nach Herzinfarkt.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

29-6-2017

FDA unveils plan to eliminate orphan designation backlog

FDA unveils plan to eliminate orphan designation backlog

Today, the U.S. Food and Drug Administration unveiled a strategic plan to eliminate the agency’s existing orphan designation request backlog and ensure continued timely response to all new requests for designation with firm deadlines. The agency’s Orphan Drug Modernization Plan comes a week after FDA Commissioner Scott Gottlieb committed to eliminating the backlog within 90 days and responding to all new requests for designation within 90 days of receipt during his testimony before a Senate subcommittee.

FDA - U.S. Food and Drug Administration

15-6-2017

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure

Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level.

FDA - U.S. Food and Drug Administration

26-5-2017

Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA (ticagrelor) 90mg tablets as a precautionary measure. This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.

FDA - U.S. Food and Drug Administration

23-3-2018

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (Active substance: Docosahexaenoic acid ethyl ester) - Orphan designation - Commission Decision (2018)1880 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/235/17

Europe -DG Health and Food Safety

21-3-2018

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Active substance: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester) - Transfer of orphan designation - Commission Decision (2018)1826 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/299/16/T/01

Europe -DG Health and Food Safety

19-3-2018

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [QPharma Inc]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [QPharma Inc]

Updated Date: Mar 19, 2018 EST

US - DailyMed

1-3-2018

01.03.2018: Mimpara 90 mg, Filmtabletten, 28 Tablette(n), 538.75, -17.4%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer56965016 PSZulassungsinhaberAmgen Switzerland AGNameMimpara 90 mg, FilmtablettenRegistrierungsdatum27.10.2004  Erstzulassung Sequenz27.10.2004ATC-KlassierungCinacalcet (H05BX01)Revisionsdatum24.01.2006WHOWHO-DDDGültig bis26.10.2019Index Therapeuticus (BSV)07.99.Packungsgrösse28 Tablette(n)Index Therapeuticus (Swissmedic)07.05.Beschreibung AbgabekategorieB  SL EintragJaAnwendungHyperparathyreoidismusFachinformationFIPatienteninform...

ODDB -Open Drug Database

6-2-2018

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [AvKARE, Inc.]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [AvKARE, Inc.]

Updated Date: Feb 6, 2018 EST

US - DailyMed

31-1-2018

Scientific guideline:  Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

17-1-2018

Omega 3 Fatty Acids

Omega 3 Fatty Acids

Omega 3 fatty acids are a lipid-regulating agent used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (500 mg/dL or greater) hypertriglyceridemia.

US - RxList

16-1-2018

Virbagen Omega (VIRBAC S.A.)

Virbagen Omega (VIRBAC S.A.)

Virbagen Omega (Active substance: recombinant omega interferon of feline origin) - Centralised - Yearly update - Commission Decision (2018)232 of Tue, 16 Jan 2018

Europe -DG Health and Food Safety

1-1-2018

01.01.2018: Invokana 300mg, Filmtabletten, 30 Tablette(n), 90.90, -11.9%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer62956006 PSZulassungsinhaberJanssen-Cilag AGNameInvokana 300mg, FilmtablettenRegistrierungsdatum29.01.2014  Erstzulassung Sequenz29.01.2014ATC-KlassierungCanagliflozin (A10BK02)Revisionsdatum WHOWHO-DDDGültig bis28.01.2019Index Therapeuticus (BSV)07.06.20.Packungsgrösse30 Tablette(n)Index Therapeuticus (Swissmedic)07.06.20.Beschreibung AbgabekategorieB  SL EintragJaAnwendungorales AntidiabetikumFachinformationFIPatienteninfor...

ODDB -Open Drug Database

29-12-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Golden State Medical Supply, Inc.]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Golden State Medical Supply, Inc.]

Updated Date: Dec 29, 2017 EST

US - DailyMed

21-12-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Teva Pharmaceuticals USA Inc]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Teva Pharmaceuticals USA Inc]

Updated Date: Dec 21, 2017 EST

US - DailyMed

28-11-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Prasco Laboratories]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Prasco Laboratories]

Updated Date: Nov 28, 2017 EST

US - DailyMed

9-11-2017

LOVAZA (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [GlaxoSmithKline LLC]

LOVAZA (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [GlaxoSmithKline LLC]

Updated Date: Nov 9, 2017 EST

US - DailyMed

25-9-2017

OMEGA-3-ACID ETHYL ESTERS Capsule [Par Pharmaceutical Inc.]

OMEGA-3-ACID ETHYL ESTERS Capsule [Par Pharmaceutical Inc.]

Updated Date: Sep 25, 2017 EST

US - DailyMed

31-8-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [American Health Packaging]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [American Health Packaging]

Updated Date: Aug 31, 2017 EST

US - DailyMed

25-8-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Par Pharmaceutical, Inc.]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [Par Pharmaceutical, Inc.]

Updated Date: Aug 25, 2017 EST

US - DailyMed

17-8-2017

TRIKLO (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [Key Therapeutics, LLC]

TRIKLO (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [Key Therapeutics, LLC]

Updated Date: Aug 17, 2017 EST

US - DailyMed

28-7-2017

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [NorthStar Rx LLC]

OMEGA-3-ACID ETHYL ESTERS Capsule, Liquid Filled [NorthStar Rx LLC]

Updated Date: Jul 28, 2017 EST

US - DailyMed

30-6-2017

01.07.2017: Stelara 90 mg, Injektionslösung in Fertigspritze, Spritze(n), 3773.50, -14.8%

ODDB.org: Open Drug DatabaseSwissmedic-Nummer61267002 PSZulassungsinhaberJanssen-Cilag AGNameStelara 90 mg, Injektionslösung in FertigspritzeRegistrierungsdatum29.10.2010  Erstzulassung Sequenz29.10.2010ATC-KlassierungUstekinumab (L04AC05)Revisionsdatum WHOWHO-DDDGültig bis28.10.2020Index Therapeuticus (BSV)07.15.PackungsgrösseSpritze(n)Index Therapeuticus (Swissmedic)07.15.Beschreibung AbgabekategorieB  SL EintragJaAnwendungPlaque-Psoriasis, Psoriasis-ArthritisFachinfo...

ODDB -Open Drug Database